In our recent publication, we investigated the dynamic relationship between quality of life (QoL) and disease progression or death in metastatic hormone-sensitive prostate cancer (mHSPC), using data from two large phase III randomised trials—ARASENS and ARANOTE. By applying joint models that simultaneously analyse longitudinal QoL trajectories and time-to-event outcomes, the study shows that patients receiving darolutamide maintained higher QoL over time versus placebo, and that QoL decline often preceded progression or death, with faster deterioration associated with a higher risk of these outcomes. These findings support routine QoL monitoring as an early marker of disease activity.
Publication details
Morgans AK, Ekberg S, Boegemann M, Paracha N, Gallagher E, Gasparini A, Crowther MJ, Shore N, Wallis CJD Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials. European Urology Oncology 2026.